Cancer Drugs | Online pharmaceuticals | Treatment for Cancer

DESCRIPTION Rapact 10mg belongs to the anti-neoplastic agent; it comes under mTOR kinase inhibitor (single transduction inhibitor). Rapact 10mg is an immunosuppressive macrolide. USED FOR Breast cancer  Patient who fails to respond to the tablet letrozole or anastrozole therapy would be treated with Rapact. Rapact 10mg is used in an advanced stage of breast cancer. Neuroendocrine tumors  Rapact 10mg involved in the treatment of some neuroendocrine tumors like pancreatic, gastrointestinal or lung cancer. Renal cell cancer  patient treating with Rapact 10mg after the failure of treatment with Sunitinib or Sorafenib. Rapact 10mg also used in the condition of; Heart, liver, kidney transplantation Waldenström macroglobulinemia Other carcinoid tumors. MECHANISM OF ACTION Rapact is the prohibition of mammalian target of rapamycin (mTOR), a serine-threonine kinase. Rapact bind with intercellular protein (FKBP-12), leads to inhibitory complex formation with mTOR complex

DESCRIPTION Rapact 5mg belongs to the anti-neoplastic agent; it comes under mTOR kinase inhibitor (single transduction inhibitor). Rapact 5mg is an immunosuppressive macrolide. USED FOR Breast cancer  Patient who fails to respond to the tablet letrozole or anastrozole therapy would be treated with Rapact. Rapact 5mg is used in an advanced stage of breast cancer. Neuroendocrine tumors  Rapact 5mg involved in the treatment of some neuroendocrine tumors like pancreatic, gastrointestinal or lung cancer. Renal cell cancer  Patient treating with Rapact 5mg after the failure of treatment with Sunitinib or Sorafenib. Rapact 5mg also used in the condition of; Heart, liver, kidney transplantation Waldenström macroglobulinemia Other carcinoid tumors. MECHANISM OF ACTION Rapact is the prohibition of mammalian target of rapamycin (mTOR), a serine-threonine kinase. Rapact bind with intercellular protein (FKBP-12), leads to inhibitory complex formation with mTOR complex 1 (mTO

DESCRIPTION Everotas 10mg belongs to the anti-neoplastic agent; it comes under mTOR kinase inhibitor (single transduction inhibitor). Everotas 10mg is an immunosuppressive macrolide. USED FOR Breast cancer  The patient who fails to respond to the tablet letrozole or anastrozole therapy would be treated with Everotas. Everotas 10mg is used in an advanced stage of breast cancer. Neuroendocrine tumors  Everotas 10mg involved in the treatment of some neuroendocrine tumors like pancreatic, gastrointestinal or lung cancer. Renal cell cancer  Patient treating with Everotas 10mg after the failure of treatment with Sunitinib or Sorafenib. Everotas 10mg also used in the condition of; Heart, liver, kidney transplantation Waldenström macroglobulinemia Other carcinoid tumors. MECHANISM OF ACTION Everotas is a prohibition of mammalian target of rapamycin (mTOR), a serine-threonine kinase. Everotas bind with intercellular protein (FKBP-12), leads to inhibitory complex formation

DESCRIPTION Everotas 5mg belongs to the anti-neoplastic agent; it comes under mTOR kinase inhibitor (single transduction inhibitor). Everotas 5mg is an immunosuppressive macrolide. USED FOR Breast cancer  The patient who fails to respond to the tablet letrozole or anastrozole therapy would be treated with Everotas. Everotas 5mg is used in an advanced stage of breast cancer. Neuroendocrine tumors  Everotas 5mg involved in the treatment of some neuroendocrine tumors like pancreatic, gastrointestinal or lung cancer. Renal cell cancer  Patient treating with Everotas 5mg after the failure of treatment with Sunitinib or Sorafenib. Everotas 5mg also used in the condition of; Heart, liver, kidney transplantation Waldenström macroglobulinemia Other carcinoid tumors. MECHANISM OF ACTION Everotas is the prohibition of mammalian target of rapamycin (mTOR), a serine-threonine kinase. Everotas bind with intercellular protein (FKBP-12), leads to inhibitory complex formation with